Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 109Specimen Handling 79Magnetic Resonance Spectroscopy 70Cisplatin 66Carboplatin 66Biopsy 57Nivolumab 56Radiotherapy 51Cyclophosphamide 50Paclitaxel 47durvalumab 38Radiation 38Gemcitabine 36olaparib 32Etoposide 32Dexamethasone 32Rituximab 30Doxorubicin 30Docetaxel 30atezolizumab 29Lenalidomide 27Ipilimumab 27Taxes 25Pemetrexed 25Bevacizumab 25Vincristine 24Cytarabine 24Prednisone 23Platinum 23Leucovorin 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Medrol Veriderm × 90 days × Clear all
NCT00792948 2026-05-29

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
97 enrolled 7 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡